The global enteral feeding formulas market was valued at USD 7.64 billion in 2024 and is projected to reach USD 10.52 billion by 2030, growing at a CAGR of 5.43% from 2025 to 2030. The growth of this market is largely driven by the increasing prevalence of chronic diseases, such as cancer, stroke, multiple sclerosis, dementia, chronic liver disease, chronic obstructive pulmonary disease (COPD), and diabetes, which often lead to difficulties in oral food intake and nutritional deficiencies. Patients suffering from these conditions frequently require specialized nutritional support to maintain strength, aid recovery, and enhance quality of life.

The enteral feeding industry is undergoing rapid innovation, spurred by advances in nutritional science, biotechnology, and medical research. Companies are increasingly focused on developing specialized, disease-specific formulas that cater to patients with unique medical needs, such as formulations tailored for diabetes, renal disorders, or critical care conditions. These customized products allow healthcare providers to deliver more precise nutrition management, reducing complications and improving patient outcomes. For instance, in May 2023, Otsuka Pharmaceutical Factory, Inc. introduced ENORAS Liquid for Enteral Use in coffee and tea flavors, addressing both nutritional requirements and patient palatability, which is crucial for long-term adherence.

Key Market Trends & Insights:

  • Regional Trends: North America dominated the global enteral feeding formulas market in 2024, capturing the largest revenue share of 30.85%. This dominance is supported by well-developed healthcare infrastructure, high awareness of clinical nutrition, and the strong presence of key market players in the region. The Asia Pacific region is projected to register the fastest CAGR over the forecast period. Factors such as rising healthcare expenditure, a growing elderly population, an increasing prevalence of chronic diseases, and expanding access to nutritional therapies are fueling strong demand in countries such as China, India, and Japan.
  • By Product Type: The standard formula segment led the market with the largest revenue share of 53.7% in 2024, as these formulations are widely prescribed for general nutritional support. The disease-specific formula segment is expected to expand at the fastest CAGR during the forecast period, driven by growing demand for personalized nutrition to manage conditions such as cancer, diabetes, or renal disorders.
  • By Feeding Flow: The intermittent feeding flow segment held the largest market share in 2024, owing to its convenience and effectiveness in home care settings. The continuous feeding flow segment is projected to grow at the fastest CAGR, particularly in hospital and critical care environments where patients require stable, controlled nutrient delivery.
  • By Age Group: The adult segment accounted for the largest revenue share in 2024, reflecting the high prevalence of chronic conditions and aging-related nutritional needs. The adult category is also expected to grow at the fastest rate, as the geriatric population continues to rise globally.
  • By Indication: The cancer care segment captured the largest market share in 2024, as nutritional therapy plays a vital role in supporting cancer patients during treatment and recovery. The other indications segment, which includes conditions such as gastrointestinal disorders, neurological disorders, and liver disease, is projected to grow at the fastest CAGR over the forecast period.
  • By Distribution Channel: The institutional sales segment dominated the market in 2024, as hospitals, clinics, and long-term care facilities remain the primary purchasers of enteral nutrition products. The online sales channel is projected to expand at the fastest CAGR, supported by the rapid rise of e-commerce in healthcare, increased accessibility, and the growing trend of home-based patient care.
  • By End-Use Setting: The home care segment held the largest revenue share in 2024, reflecting the shift toward cost-effective, patient-friendly, and long-term enteral nutrition solutions administered outside of hospitals. The hospital segment is anticipated to register the fastest growth, driven by rising hospitalizations, greater adoption of enteral feeding in critical care, and the need for advanced clinical nutrition support in acute care settings.

Order a free sample PDF of the Enteral Feeding Formulas Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

  • 2024 Market Size: USD 7.64 Billion
  • 2030 Projected Market Size: USD 10.52 Billion
  • CAGR (2025-2030): 5.43%
  • North America: Largest market in 2024
  • Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The global enteral feeding formulas market is moderately consolidated, with several multinational corporations leading innovation, product development, and market expansion strategies.

  • Abbott: Abbott has a strong global presence in nutritional products and continues to introduce innovations to meet evolving consumer and patient demands. In September 2021, Abbott responded to the rising demand for plant-based and organic nutrition by launching Ensure Harvest and relaunching PediaSure Harvest, both formulated with plant-based protein and organic food ingredients. These offerings reflect Abbott’s commitment to diversified, patient-friendly nutrition solutions.
  • Danone S.A.: Danone is a prominent player in the global nutrition market, with its medical nutrition division offering a wide range of enteral feeding products. Its portfolio emphasizes patient-centered formulations, including products for chronic disease management and pediatric nutrition.
  • Fresenius Kabi AG: Fresenius Kabi is a leading provider of clinical nutrition and enteral feeding solutions worldwide. The company is recognized for its expertise in parenteral and enteral nutrition, offering tailored products for use in hospitals, home care, and long-term care facilities.
  • Nestlé Health Science: Nestlé has a strong footprint in enteral nutrition through its Nestlé Health Science division, delivering a diverse range of enteral formulas targeted at both general and disease-specific conditions. Its global distribution network makes it a key competitor in the market.
  • Meiji Holdings and Mead Johnson & Company, LLC: These companies are also significant contributors, offering specialized formulas and expanding their portfolios to meet rising demand for nutritional products across Asia, North America, and other global markets.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The enteral feeding formulas market is set for steady growth, fueled by the rising prevalence of chronic diseases, an aging population, and advances in specialized nutritional solutions. While North America leads the market, Asia Pacific is projected to expand the fastest, with increasing demand for personalized, convenient, and patient-focused nutrition solutions driving future growth.